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The primary structure of a new sarafotoxin, SRTX-d, from the venom of ~zract~~js e~gud~~s~ is described. SRTX-d 
differs from SRTX-b in two substitutions: Ile19 instead of Val and ThrZ instead of Ser. The toxicity of SRTX-d and its 
vasoconstriction potency are very low in comparison to SRTX-a and SRTX-b, whereas its IC,, for *ZSI-SRTX-b binding 
is similar to that of SRTX-b. It is suggested that the Thr to Ser substitution, which is shared by two additional weak 
members of the endothelin/sarafotoxin family, SRTX-c and ET-3, affects the biological activity of SRTX-d as well. 
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1. INTRODUCTION 
Since the discovery of the mammalian en- 
dothelins and the sarafotoxins from the venom of 
the snake Atractaspis engaddensis [l-3], attempts 
were made to define the domains which are essen- 
tial for specific binding to receptors, immunoreac- 
tivity and vasoconstriction activity 14-71. These 
attempts were approached by (i) using modified 
versions of the peptides and (ii) comparison of the 
structure/function relationships of the various 
natural peptides [6,7]. The latter approach was 
quite fruitful as it pointed to the importance for 
activity of the N-terminal half of the molecule in 
addition to the C-terminal tail. We have stressed 
previously the importance of the Thr to Ser 
substitution in position 2 in both SRTX-c and 
ET-3, the weakest members of the en- 
dothelin/sarafotoxin family 18.91. The difference 
between the two amino acids, however, appeared 
too small in order to explain such differences in ac- 
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tivity, and the reduction in activity was therefore 
ascribed to the other substitutions found in these 
two molecules. 
We have now established the amino acid se- 
quence of SRTX-d, an additional sarafotoxin; this 
isotoxin differs from SRTX-b in two substitutions, 
again threonine instead of serine in position 2 and 
isoleucine instead of valine in position 19. The lat- 
ter substitution is found in all ETs described thus 
far, including the vasoactive intestinal contractor 
peptide (VIC) reported recently [lo], but in none 
of the SRTXs. SRTX-d shows a very low potency 
in vasoconstriction, a weak toxic activity, but a 
high binding affinity to aorta1 preparations* 
2. EXPERIMENTAL 
SRTX-b was isolated and purified from the venom of Amc- 
taspis engaddensis as described previously [2,3]. SRTX-d was 
purified from fraction S6a of the DEAE-cellulose step [3] by 
reverse phase chromatography on a Lichrosorb RP-18 column 
(2.50 x 4 mm, Merck, Darmstadt, FRG); the column was 
developed at 1 ml/min with a linear gradient of O-80% 
acetonitrile in 0.1% trifluoroacetic acid (TFA) using a Gilson 
model 303 HPLC system. Two protein peaks with retention 
times of 26.8 min and 29.7 min were obtained; the first, larger 
peak corresponded to SRTX-a; the second peak is here 
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designated as sarafotoxin-d (SRTX-d). The latter peak was 
rechromatographed on the same system before further analysis. 
Amino acid analysis was carried out by AminoLab (Rehovot, 
Israel) on samples hydrolyzed in 6 N HCI in evacuated sealed 
tubes at 110°C for 22 h. Cysteine was estimated as cysteic acid 
after performic acid oxidation. 
Sequence analysis of the pyridylethylated reduced peptide 
[l 11 or the untreated peptide was performed at the Department 
of Virology, Weizmann Institute of Science (Rehovot, Israel) 
using a model 470A liquid phase protein sequencer with an 
online model 12OA PTH analyzer (Applied Biosystems, Inc.). 
C-terminal sequence analysis was performed with 
carboxypeptidase-Y. An amount of 15Opg of SRTX-d was in- 
cubated with 50 fig of the enzyme in 0.1 M pyridine-acetate buf- 
fer, pH 5.5, 5 &ml pepstatin, 1 mM EDTA, at 37°C. Samples 
containing 25 pg SRTX-d were withdrawn at 0, 10 and 60 min 
and at 24 h. The samples were then analyzed for amino acid 
composition. 
Binding competition experiments were performed with 5 nM 
‘2SI-SRTX-b as radioligand. The particulate fraction of rabbit 
aorta was prepared according to Gurwitz et al. [12] with 25 mM 
Tris-HCI buffer, pH 7.4, containing EDTA, EGTA and pro- 
tease inhibitors. Aliquots of 50~1 containing about 2OOpg 
protein were incubated for 45 min at 30°C with various concen- 
trations of SRTX-b or SRTX-d in Tris buffer (totai volume 
ZOO,&. The reaction was terminated by the addition of 3 ml 
ice-cold buffer followed by centrifugation at 4000 x g for 
15 min at 4’C. The precipitates were then washed twice with 
3 ml cold buffer. For nonspecific binding, incubation was car- 
ried out in the presence of 2pM unlabeled SRTX-b. Assays 
were performed in triplicate. Data are expressed as specific 
binding (total, minus nonspecific). 
Vasoconstriction was examined on isolated rabbit aorta strips 
(opened rings) as detailed previously [7]. 
3. RESULTS AND DISCUSSION 
The primary structure of SRTX-d was determin- 
ed by automatic sequencing and verified by amino 
acid analysis; in addition, carboxypeptidase diges- 
tion of the C-terminal tail was carried out up to the 
amino acid residue at position 19 (He). The results 
show that this isotoxin differs from SRTX-a in 
three positions, IIe19 instead of Val, Tyr13 instead 
of Asn and Thr2 instead of Ser and from SRTX-b 
in two - Ile19 instead of Val and Thr’ instead of 
Ser (fig. 1). The Thr to Ser substitution is probably 
very important as it is shared by two additional 
‘weak’ members of the endotheIin/sarafotoxin 
family, SRTX-c and ET-3, with apparently con- 
siderable functional implications (see below). In 
order to ascertain this finding we have performed 
several sequence analyses using unmodified and 
reduced and alkylated peptide preparations; in all 
cases Thr clearly appeared in the second (as well as 
in 7th) position and the amino acid composition of 
SRTX-d showed two threonine residues and no 
significant amount of serine, as expected from the 
amino acid sequence. 
The toxicity of SRTX-d, as determined by i.v. 
injections, showed an LDse of about 350 rig/g 
mouse; this toxicity is very low in comparison with 
SRTX-a and b and ET-l (LD~o of all three is about 
10 rig/g)) and is within the toxicity range of SRTX- 
c [91. 
Radioligand binding experiments in brain (not 
shown) and aorta showed that SRTX-d competes 
with ‘251-SRTX-b with an ICSO similar to that of 
SRTX-b (fig.2). 
In the vasoconstriction experiments, cumulative 
doses as high as 40 n&I of SRTX-d did not elicit 
any noticeable response. Higher doses induced a 
Cys-Ser-Cys-Lys-Asp-Met-Thr-Asp-Lys-Glu-Cys-Leu-Asn-Phe-Cys-His-Gln-Asp-Val-1le-T~ 
Cys-Ser-Cys-Lys-Asp-Met-Thr-Asp-Lys-Glu-Cys-Leu-Tyr-Phe-Cys-His-GIn-Asp-Val-Ile-Trp 
Cys-Tnr-Cys-Lys-Asp-Met-Thr-Asp-Lys-Clu-Cys-Leu-Tyr-Phe-Cys-His-Gln-Asp-Ile-Ile-Trp 
Cys-Thr-Cys-Asn-Asp-Met-Thr-Asp-Glu-Glu-Cys-Leu-Asn-Phe-Cys-His-Gln-Asp-Val-Ile-Trp 
Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp 
Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp 
Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp 
Cys-Ser-Cys-Asn-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp 
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Fig.1. Amino acid sequence of SRTX-d in comparison with the other sarafotoxins and endothelins. 
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Fig.2. Inhibition of ‘2SI-SRTX-b binding to the particulate 
fraction of rabbit aorta. Competition binding assays were as 
described in section 2, using 5 nM “‘1-SRTX-b and various 
concentrations of SRTX-b and SRTX-d. 
concentration-dependent contraction, which was 
weaker than the contraction induced by SRTX-b 
by one to two orders of magnitude (fig.3). The cor- 
responding EDso values (i.e. the cumulative doses 
that induce half maximal responses) for SRTX-b 
and SRTX-d were about 5 nM and 90 nM respec- 
tively; the maximum isometric tension (+ SD) in- 
duced by SRTX-d was 0.4 + 0.01 g. This is about 
26% of the maximum tension induced by SRTX-b 
or norepinephrine (see also [7]). 
It is thus evident that SRTX-d is a considerably 
weaker vasoconstrictor than either SRTX-a, 
SRTX-b or ET-l [7]; it is also less toxic by more 
than one order of magnitude, yet its affinity to 
binding sites in the rabbit aorta is similar to that of 
SRTX-b. It should be stressed here again that 
SRTX-d differs from SRTX-b in two substitu- 
tions, which apparently do not affect binding in 
the aorta, but cause considerably lower lethality 
and vasoconstrictor potency. A similar trend in ac- 
tivity is shown by SRTX-c and, to a certain degree, 
also by ET-3, which share the Thr’/Ser substitu- 
tion (in addition to several others) ([9] and un- 
published results). We conclude that it is the 
change in position 2 which is most probably 
responsible for the differences observed between 
the weak Thr2 peptides and the others, as it is the 
only substitution common to all of them and 
found in none of the others. 
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Fig.3. Contractile dose response of rabbit aorta strips to 
cumulatively applied SRTX-b (mean + SE, n = 10) and SRTX- 
d (n = 2). Responses are expressed as % of maximal contraction 
induced by SRTX-b. 
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